These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 17454035)
21. Influence of operational variables on properties of piroxicam pellets prepared by extrusion-spheronization: a technical note. Sinha VR; Agrawal MK; Kumria R; Bhinge JR AAPS PharmSciTech; 2007 Mar; 8(1):20. PubMed ID: 17408219 [TBL] [Abstract][Full Text] [Related]
22. Dissolution properties of piroxicam powders and capsules as a function of particle size and the agglomeration of powders. Swanepoel E; Liebenberg W; de Villiers MM; Dekker TG Drug Dev Ind Pharm; 2000 Oct; 26(10):1067-76. PubMed ID: 11028221 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and in vitro release study of ibuprofen-loaded gelatin graft copolymer nanoparticles. Haroun AA; El-Halawany NR; Loira-Pastoriza C; Maincent P Drug Dev Ind Pharm; 2014 Jan; 40(1):61-5. PubMed ID: 23244199 [TBL] [Abstract][Full Text] [Related]
24. Nanoemulsifying drug delivery system to improve the bioavailability of piroxicam. Motawea A; Borg T; Tarshoby M; Abd El-Gawad AE Pharm Dev Technol; 2017 May; 22(3):445-456. PubMed ID: 27583581 [TBL] [Abstract][Full Text] [Related]
25. Co-processed MCC-Eudragit® E excipients for extrusion-spheronization. Goyanes A; Souto C; Martínez-Pacheco R Eur J Pharm Biopharm; 2011 Nov; 79(3):658-63. PubMed ID: 21827853 [TBL] [Abstract][Full Text] [Related]
26. Transbuccal permeation, anti-inflammatory activity and clinical efficacy of piroxicam formulated in different gels. Attia MA; El-Gibaly I; Shaltout SE; Fetih GN Int J Pharm; 2004 May; 276(1-2):11-28. PubMed ID: 15113610 [TBL] [Abstract][Full Text] [Related]
27. [Analgesic activity of cinnoxicam. Findings of clinical sensimetry]. Biasi G; Piazzini M; Fioravanti A; Francioni C; Marcolongo R Clin Ter; 1989 Dec; 131(5):315-9. PubMed ID: 2532585 [TBL] [Abstract][Full Text] [Related]
29. Micromeritic and packing properties of diclofenac pellets and effects of some formulation variables. Rodriguez EC; Torrado JJ; Nikolakakis I; Torrado S; Lastres JL; Malamataris S Drug Dev Ind Pharm; 2001 Sep; 27(8):847-55. PubMed ID: 11699837 [TBL] [Abstract][Full Text] [Related]
30. Accelerated ketoprofen release from polymeric matrices: importance of the homogeneity/heterogeneity of excipient distribution. Gue E; Willart JF; Muschert S; Danede F; Delcourt E; Descamps M; Siepmann J Int J Pharm; 2013 Nov; 457(1):298-307. PubMed ID: 24076398 [TBL] [Abstract][Full Text] [Related]
32. Formulation of Niosomal Gel for Enhanced Transdermal Lornoxicam Delivery: In-Vitro and In-Vivo Evaluation. El-Ridy MS; Yehia SA; Mohsen AM; El-Awdan SA; Darwish AB Curr Drug Deliv; 2018; 15(1):122-133. PubMed ID: 28240177 [TBL] [Abstract][Full Text] [Related]
33. Effect of the surfactant on the availability of piroxicam as a poorly hydrosoluble drug from suppositories. Dal Zorro M; Franceschinis E; Punchina A; Realdon N Pharmazie; 2012 Jan; 67(1):37-45. PubMed ID: 22393829 [TBL] [Abstract][Full Text] [Related]
34. Immediate release of poorly soluble drugs from starch-based pellets prepared via extrusion/spheronisation. Dukić-Ott A; Remon JP; Foreman P; Vervaet C Eur J Pharm Biopharm; 2007 Nov; 67(3):715-24. PubMed ID: 17537625 [TBL] [Abstract][Full Text] [Related]
35. Development of Biodegradable Injectable In situ Forming Implants for Sustained Release of Lornoxicam. Christian R; Thakkar V; Patel T; Gohel M; Baldaniya L; Shah P; Pandya T; Gandhi T Curr Drug Deliv; 2019; 16(1):66-78. PubMed ID: 30264681 [TBL] [Abstract][Full Text] [Related]